The content of this website is intended for United States audiences only.
A Phase 1b Randomized, Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-8588 in People With HIV-1 Who are Virologically Suppressed on Antiretroviral Therapy
The primary objective of this study was to learn how safe and tolerable, single and multiple doses of GS-8588 were in participants with well-controlled HIV-1.
Age
18 Years +
Sex
ALL
Healthy Volunteers
No
Medical Condition
HIV-1
Gender
N/A
Date
Study Type
INTERVENTIONAL
Study Phase
PHASE1b
Product
Share Trial